Zephyr® Endobronchial Valve
The Zephyr® Endobronchial Valve is an endoscopic lung volume reduction therapy that has been proven to significantly improve lung function, exercise capacity and quality of life for emphysema patients across four randomized, controlled clinical trials and in 20,000 patients worldwide.
In combination with its diagnostic companion products, it uniquely offers a prospectively proven method for predicting responders. It is also designed to be removable, preserving future treatment options for patients.
The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves and now considers current evidence sufficient to support routine use. The change in NICE guidance is based on safety and efficacy data from multiple randomized clinical trials evaluating the Zephyr EBV, which has demonstrated clinical and quality of life benefits, and long-term safety for eligible patients.
With the valves, we can treat patients who did not have any treatment options before.
This is one of the best technologies for our end stage patient.
In the right patient, the Zephyr is always going to be my first choice.